beta
IA Trial Radar
Un estudio coincide con los criterios de filtro
Vista de tarjeta
Volver a la búsqueda

Continuous Glucose Monitoring System (CGM)-Informed Bolus Calculator Study 25

Completado
Los detalles del ensayo clínico están disponibles principalmente en inglés. ¡Sin embargo, IA Trial Radar puede ayudar! Simplemente haga clic en 'Explicar el estudio' para ver y discutir la información del estudio en el idioma que haya seleccionado.
El ensayo clínico NCT04320069 fue un estudio intervencionista para Diabetes tipo 1. Su estado actual es: completado. El estudio se inició el 9 de junio de 2020, con el objetivo de reclutar a 25 participantes. Dirigido por Insulet Corporation, la fecha de finalización prevista fue el 29 de septiembre de 2020. Los datos se actualizaron por última vez en ClinicalTrials.gov el 13 de noviembre de 2023.
Resumen
Subjects will use the Omnipod Horizon™ System in Manual Mode in an outpatient setting for 14-days. Subjects will be trained to use the Manual Mode feature of the Omnipod Horizon™ System including how to use the bolus calculator using manual entry of blood glucose values or by using the CGM-informed bolus calculator.
Descripción detallada
The study schedule consists of two outpatient phases:

  1. 7 days of Omnipod Horizon™ use in Manual Mode without a connected CGM using manual entry of BG values to deliver boluses (Phase 1) followed by;
  2. 7 days of Omnipod Horizon™ use in Manual Mode with a connected CGM using the CGM-informed bolus calculator to deliver boluses (Phase 2)

Following subject screening, system training and enrollment, subjects will com...

Mostrar más
Título oficial

Evaluating the Safety and Effectiveness of the Omnipod Horizon™ CGM-informed Bolus Calculator in Patients With Type 1 Diabetes

Condiciones médicas
Diabetes tipo 1
Publicaciones
Artículos científicos y trabajos de investigación publicados sobre este estudio clínico:
Otros ID del estudio
  • G200018
Número del NCT
NCT04320069
Inicio del estudio (real)
2020-06-09
Última actualización
2023-11-13
Fecha de finalización (estimada)
2020-09-29
Inscripción (prevista)
25
Tipo de estudio
Intervencionista
FASE
N/A
Estado general
Completado
Palabras clave
T1D
Omnipod
Objetivo principal
Tratamiento
Método de asignación
N/A
Modelo de intervención
Grupo único
Enmascaramiento
Ninguno (Abierto)
Brazos / Intervenciones
Grupo de participantesIntervención/Tratamiento
ExperimentalOmnipod Horizon™ Automated Glucose Control System
All subjects using the Omnipod Horizon™ Automated Glucose Control System in Manual Mode without a connected CGM for 7 days and with a connected CGM for 7 days.
Omnipod Horizon™ Automated Glucose Control System
Omnipod Horizon™ Automated Glucose Control System use in Manual Mode
Resultado primario
Medida de resultadoDescripción de la medidaPeriodo de tiempo
Percentage of Time <70 mg/dL
Glucose metric from continuous glucose monitoring system (CGM)
Phase 2 compared to Phase 1 (comparing the 4-hour post bolus period)
Percentage of Time >180 mg/dL
Glucose metric from continuous glucose monitoring system (CGM)
Phase 2 compared to Phase 1 (comparing the 4-hour post bolus period)
Resultado secundario
Medida de resultadoDescripción de la medidaPeriodo de tiempo
Mean Glucose
Glucose metric from continuous glucose monitoring system (CGM)
Phase 2 compared to Phase 1 (comparing the 4-hour post bolus period)
Percentage of Time <54 mg/dL
Glucose metric from continuous glucose monitoring system (CGM)
Phase 2 compared to Phase 1 (comparing the 4-hour post bolus period)
Percentage of Time ≥ 250 mg/dL
Glucose metric from continuous glucose monitoring system (CGM)
Phase 2 compared to Phase 1 (comparing the 4-hour post bolus period)
Percentage of Time ≥ 300 mg/dL
Glucose metric from continuous glucose monitoring system (CGM)
Phase 2 compared to Phase 1 (comparing the 4-hour post bolus period)
Percentage of Time in Range 70-180 mg/dL
Glucose metric from continuous glucose monitoring system (CGM)
Phase 2 compared to Phase 1 (comparing the 4-hour post bolus period)
Mean Glucose
Glucose metric from continuous glucose monitoring system (CGM)
Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall
Percentage of Time <54 mg/dL
Glucose metric from continuous glucose monitoring system (CGM)
Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall
Percentage of Time <70 mg/dL
Glucose metric from continuous glucose monitoring system (CGM)
Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall
Percentage of Time >180 mg/dL
Glucose metric from continuous glucose monitoring system (CGM)
Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall
Percentage of Time ≥ 250 mg/dL
Glucose metric from continuous glucose monitoring system (CGM)
Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall
Percentage of Time ≥ 300 mg/dL
Glucose metric from continuous glucose monitoring system (CGM)
Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall
Percentage of Time in Range 70-180 mg/dL
Glucose metric from continuous glucose monitoring system (CGM)
Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall
Percentage of Time in Range 70-140 mg/dL
Glucose metric from continuous glucose monitoring system (CGM)
Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall
Standard Deviation
Glucose metric from study continuous glucose monitoring system (CGM)-measured glucose variability with the standard deviation (SD)
Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall
Coefficient of Variation
Glucose metric from study continuous glucose monitoring system (CGM)-measured glucose variability with the coefficient of variation (CV)
Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall
Criterios de elegibilidad

Criterios de edad
Niño, Adulto, Adulto mayor
Edad mínima
2 Years
Criterios de sexo
Todos
  1. Age at time of consent/assent 2-70 years
  2. Subjects aged < 18 years must be living with parent/legal guardian
  3. Diagnosed with type 1 diabetes for at least 6 months. Diagnosis is based on investigator's clinical judgment
  4. Must be a current Omnipod user, or have used an Omnipod in the past
  5. Investigator has confidence that the subject, parent, or legal guardian, can successfully operate all study devices and can adhere to the protocol
  6. Willing to use only the following types of Insulin during the study: Humalog, Novolog, Admelog, or Apidra
  7. Must be willing to use the Omnipod Horizon™ in Manual Mode only and agree not to use Automated Mode functionality
  8. Must be willing to use the Omnipod Horizon™ bolus calculator without a connected CGM for the first 7-days of Manual Mode (Phase 1) while manually entering BG values to deliver boluses
  9. Must be willing to use the Omnipod Horizon™ bolus calculator with a connected CGM for the last 7-days of Manual Mode (Phase 2) using the CGM-informed bolus calculator to deliver boluses
  10. Willing to wear the system continuously throughout the study
  11. For subjects not currently enrolled in the Omnipod Horizon™ Pivotal Study (G190270), A1C <10%
  12. Must be willing to use the Dexcom App on the Omnipod Horizon™ PDM as the sole source of Dexcom data (except for the Dexcom Follow App)
  13. Able to read and speak English fluently (if subject is a young child then Caregiver must meet the criteria)
  14. Willing and able to sign the Informed Consent Form (ICF) and/or has a parent/guardian willing and able to sign the ICF. Assent will be obtained from subjects aged < 18 years per State requirements.
  15. For subjects aged 2-5.9 years of age, parents or trained caregivers agree to be physically present during the decision and delivery of insulin boluses for this age group, as well as agree to be available for glucose monitoring and treatment during the 4-hour post bolus period.

  1. A medical condition, which in the opinion of the investigator, would put the subject at an unacceptable safety risk
  2. History of severe hypoglycemia in the past 6 months
  3. History of DKA in the past 6 months, unrelated to an intercurrent illness or infusion set failure
  4. Plans to receive blood transfusion over the course of the study
  5. Currently diagnosed with anorexia nervosa or bulimia
  6. Acute or chronic kidney disease or currently on hemodialysis
  7. History of adrenal insufficiency
  8. Has taken oral or injectable steroids within the past 8 weeks or plans to take oral or injectable steroids during the study
  9. Unable to tolerate adhesive tape or has any unresolved skin condition in the area of sensor or pump placement
  10. Plans to use insulin other than U-100 insulin intended for use in the study device during the study
  11. Use of non-insulin anti-diabetic medication other than metformin (e.g. GLP1 agonist, SGLT2 inhibitor, DPP-4 inhibitor, pramlintide)
  12. Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the previous 12 months
  13. Clinical signs of hypothyroidism and hyperthyroidism
  14. Pregnant or lactating, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD or implant)
  15. Currently participating or plans to participate in another clinical study using an investigational drug or device other than Omnipod Horizon™. Subjects may be recruited from the Omnipod Horizon Pivotal Study (G190270) prior to their recommencement of the pivotal study after study pause.
  16. Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the investigator's clinical judgment
Insulet Corporation logoInsulet Corporation
No hay datos de contacto.
4 Centros del estudio en 1 países

California

Sansum Diabetes Research Institute, Santa Barbara, California, 93105, United States

Colorado

University of Colorado Denver, Denver, Colorado, 80045, United States

Georgia

Atlanta Diabetes, Atlanta, Georgia, 30318, United States

Virginia

University of Virginia, Charlottesville, Virginia, 22904, United States